Sutezolid: Oxazolidinone antibacterial treatment of tuberculosis

J. P. Lanoix; E. Nuermberger

doi:10.1358/dof.2013.038.06.1965098

Sutezolid: Oxazolidinone antibacterial treatment of tuberculosis

J. P. Lanoix, E. Nuermberger

School of Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

In the context of increasing drug resistance among Mycobacterium tuberculosis (Mtb) strains, new, potent and well tolerated drugs are urgently needed. Bedaquiline has obtained accelerated approval, but additional novel agents are needed to enable effective combination chemotherapy of extensively drug-resistant tuberculosis (TB). Linezolid, the first and only marketed oxazolidinone antibiotic, has shown certain activity against Mtb. However, serious safety concerns related to long-term administration have limited its utility for TB treatment. Sutezolid (formerly PNU-100480) is a thiomorpholine analogue of linezolid with greater potency in several experimental TB models and the potential for a superior safety profile. This article reviews available preclinical and clinical data regarding the pharmacokinetics, safety and efficacy of sutezolid and presents the case for its further development for the treatment of TB.

Original language	English (US)
Pages (from-to)	387-394
Number of pages	8
Journal	Drugs of the Future
Volume	38
Issue number	6
DOIs	https://doi.org/10.1358/dof.2013.038.06.1965098
State	Published - Jun 2013

Keywords

Antibiotic
Mycobacterium tuberculosis
PNU-100480
Suterzolid
Thiomorpholine analogue

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2013.038.06.1965098

Cite this

@article{70c8450ac336441e8efc19a15c050910,

title = "Sutezolid: Oxazolidinone antibacterial treatment of tuberculosis",

abstract = "In the context of increasing drug resistance among Mycobacterium tuberculosis (Mtb) strains, new, potent and well tolerated drugs are urgently needed. Bedaquiline has obtained accelerated approval, but additional novel agents are needed to enable effective combination chemotherapy of extensively drug-resistant tuberculosis (TB). Linezolid, the first and only marketed oxazolidinone antibiotic, has shown certain activity against Mtb. However, serious safety concerns related to long-term administration have limited its utility for TB treatment. Sutezolid (formerly PNU-100480) is a thiomorpholine analogue of linezolid with greater potency in several experimental TB models and the potential for a superior safety profile. This article reviews available preclinical and clinical data regarding the pharmacokinetics, safety and efficacy of sutezolid and presents the case for its further development for the treatment of TB.",

keywords = "Antibiotic, Mycobacterium tuberculosis, PNU-100480, Suterzolid, Thiomorpholine analogue",

author = "Lanoix, {J. P.} and E. Nuermberger",

year = "2013",

month = jun,

doi = "10.1358/dof.2013.038.06.1965098",

language = "English (US)",

volume = "38",

pages = "387--394",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "6",

}

TY - JOUR

T1 - Sutezolid

T2 - Oxazolidinone antibacterial treatment of tuberculosis

AU - Lanoix, J. P.

AU - Nuermberger, E.

PY - 2013/6

Y1 - 2013/6

N2 - In the context of increasing drug resistance among Mycobacterium tuberculosis (Mtb) strains, new, potent and well tolerated drugs are urgently needed. Bedaquiline has obtained accelerated approval, but additional novel agents are needed to enable effective combination chemotherapy of extensively drug-resistant tuberculosis (TB). Linezolid, the first and only marketed oxazolidinone antibiotic, has shown certain activity against Mtb. However, serious safety concerns related to long-term administration have limited its utility for TB treatment. Sutezolid (formerly PNU-100480) is a thiomorpholine analogue of linezolid with greater potency in several experimental TB models and the potential for a superior safety profile. This article reviews available preclinical and clinical data regarding the pharmacokinetics, safety and efficacy of sutezolid and presents the case for its further development for the treatment of TB.

AB - In the context of increasing drug resistance among Mycobacterium tuberculosis (Mtb) strains, new, potent and well tolerated drugs are urgently needed. Bedaquiline has obtained accelerated approval, but additional novel agents are needed to enable effective combination chemotherapy of extensively drug-resistant tuberculosis (TB). Linezolid, the first and only marketed oxazolidinone antibiotic, has shown certain activity against Mtb. However, serious safety concerns related to long-term administration have limited its utility for TB treatment. Sutezolid (formerly PNU-100480) is a thiomorpholine analogue of linezolid with greater potency in several experimental TB models and the potential for a superior safety profile. This article reviews available preclinical and clinical data regarding the pharmacokinetics, safety and efficacy of sutezolid and presents the case for its further development for the treatment of TB.

KW - Antibiotic

KW - Mycobacterium tuberculosis

KW - PNU-100480

KW - Suterzolid

KW - Thiomorpholine analogue

UR - http://www.scopus.com/inward/record.url?scp=84930538823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930538823&partnerID=8YFLogxK

U2 - 10.1358/dof.2013.038.06.1965098

DO - 10.1358/dof.2013.038.06.1965098

M3 - Review article

AN - SCOPUS:84930538823

SN - 0377-8282

VL - 38

SP - 387

EP - 394

JO - Drugs of the Future

JF - Drugs of the Future

IS - 6

ER -

Sutezolid: Oxazolidinone antibacterial treatment of tuberculosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this